Ken Mullen has over 15 years experience in building revolutionary data-driven biotechnology companies in the Boston area.

Currently at Warp Drive Bio, a company responsible for re-invigorating natural product drug discovery and a recipient of record-setting funding, he is responsible for several areas of business and lab operations. The company’s revolutionary use of next generation sequencing, the resulting big data and proprietary analysis continue to push through the boundaries of several established disciplines.

Prior to Warp Drive Bio, Mr. Mullen was the third employee of Foundation Medicine, a company that has in short order established itself at the standard for next-gen driven diagnostics with a market cap over $1 billion as of 2015. At Foundation, he headed operations through the development of the commercial FoundationOne test, the product of cutting-edge tumor sequencing and patient-focused analysis. He was also responsible for the design and build of FMI’s first CLIA lab in Cambridge.

Prior to Foundation Medicine, he served as SVP of Operations with CombinatoRx, an early pioneer in combination drug therapy. At CRXX he led the team responsible for the development of the proprietary Chalice LIMS and analysis system. CombinatoRx used this system and its cHTS hardware counterpart, to discover its novel therapeutics. This system and its contemporary counterpart have benefitted many collaborators and continues in use today as the core offering for Horizon CombinatoRx. While at CRXX, Mr. Mullen managed the vision, design, architecture and completion of a 75,000SF build-out in Kendall Square. He was responsible for operations comprising of Facilities, IT and Informatics through periods of significant growth including a successful IPO and the establishment of a subsidiary in Singapore.